" class="no-js "lang="en-US"> Toragen Announces Appointment of Chief Scientific Officer
Friday, March 31, 2023

Breaking News

NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors
Toragen Announces Appointment of Chief Scientific Officer | MTA

February 9 2023

Toragen Announces Appointment of Chief Scientific Officer

Toragen, a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus, announced today that it has promoted Rick Lumpkin, PhD to the role of Chief Scientific Officer.

Dr. Lumpkin joined Toragen in late 2018 as a consultant and became a fulltime employee in mid-2022. Sandra Coufal, MD, Toragen CEO said, “We are thrilled to have Rick as our Chief Scientific Officer as he brings over 30 years of significant experience in early-stage biotechnology companies and synthetic chemistry. Rick has already made important discoveries at Toragen and has directed the foundational science to swiftly proceed to the clinic.”

Prior to Toragen, Dr. Lumpkin served as a founding employee at Global Blood Therapeutics, Portola Pharmaceuticals and Millennium Pharmaceuticals. Additionally, Dr. Lumpkin brings experience from COR Therapeutics, Ribogene, Amylin and Corvas International, Inc.

  1. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business

    Drug Development

     Read more
  2. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions

    Appointments

     Read more
  3. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board

    Appointments

     Read more
  4. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China

    Diseases

     Read more
  5. Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)

    Clinical Trials

     Read more
More On